Clients
Since our inception in 2012, the strategic intelligence we provided has been highly appreciated by clients worldwide.
Their feedback praised the outstanding level of our reports and our expertise.
We have already seen a number of repeat customers, distinguishing the uniqueness and quality of our reports.
Testimonials
Names and titles as of when comment written
Stefano Buono
Chairman and CEO
Advanced Accelerator Applications USA, Inc.
New York, NY, USA
"We appreciated that MEDraysintell nuclear medicine report is comprehensive and gives a worldwide view of the nuclear medicine market’s current situation and evolution, with a special focus on therapy, which has been neglected for long time in molecular nuclear medicine reports in the past. For somebody new in AAA, it has been a very good starting point in clarifying a shared vision of the nuclear diagnostic and therapeutic markets. It allowed new staff to get a global view on the situation but also to deep dive into each radionuclide, radiopharmaceuticals, companies, etc... We would recommend this report and would use MEDraysintell service again if need be.”
Nicolas Serandour
Chief Financial Officer
Advanced Oncotherapy plc
London, UK
“MEDraysintell report on proton therapy is unique, no other reports was able to bring that level of expertise in such a niche but growing market. We appreciate the fact that it has been written by experts, who are responsive and coming from that very specific industry. This comprehensive report provide us with strategic insights about the proton therapy world that is helping us understand the market as we are developing the next generation proton therapy systems for cancer treatment. I’m waiting for the next edition.”
Rosanne Robinson
General Manager
Australian Nuclear Science & Technology Organisation
Sydney, Australia
"The MEDraysintell nuclear medicine report is the most comprehensive report available globally. It is prepared by team of international experts in the field and is the only report that covers the depth and breadth of the industry. It is suitable for researchers, early stage development companies as well as established players. It contains detailed information on all aspects of the industry. The report is invaluable to support the development of business plans and marketing decisions and is widely consulted within our organisation. The reports are also a great resource for new team members who want to understand nuclear medicine and the future of the market. I highly recommend this report."
Friedrich-W. Gause
Managing Director and Co-Founder
BGM Associates GmbH
Berlin, Germany
"MEDraysintell Nuclear Medicine report certainly provides the most comprehensive industry insight with a wealth of valuable information on radiopharmaceutical products, projects and companies. The report complements our strategic analysis of market and competitive dynamics in SPECT and PET molecular imaging. I would recommend the report for industry players looking for project development and product licensing partnerships as well as for equity investors. Should the opportunity arise, I would rather likely use MEDraysintell services again."
Camille Chevalier
Associate
Boston Consulting Group
Paris, France
"Boston Consulting Group was mandated by a leading Private Equity firm to understand the dynamics of the Nuclear Medicine market worldwide. Richard Zimmermann’s and Paul-Emmanuel Goethals’ work and support were instrumental for us to conduct our analyses and acquire a clear view on the latest medical innovations & related patents, and on the market players behind, regardless of geographies since their reports are truly exhaustive. It was also an easy way for us in a short amount of time to have access to data about underlying drivers for the SPECT and PET markets, documented by well-known specialists on the topic.”
Ludwig Camusot
Chief Executive Officer
Camel-IDS NV
Brussels, Belgium
"As a new comer in the radiopharmaceutical world, I really adopted this report as a crash course to Nuclear Medicine. I could find easily all needed informations to get a good grasp of this fascinating market: business insights, technical aspects and future outlooks. I certainly recommend it to anyone, familiar or not, who wants to understand what Nuclear Medicine will look like tomorrow."
Dr. Dirk Freitag-Stechl, M.B.A.
Managing Partner
CUP Laboratorien Dr. Freitag GmbH
Radeberg Saxony, Germany
"As a medium-sized pharmaceutical contract laboratory with more than 10 years of experience in the field of radiopharmacy, we are currently expanding our range of services in this area and making considerable investments in technology and personnel.
MEDraysintell's current report on nuclear medicine was an essential and valuable basis for our business plan. It contains a very good overall view of the industry and also good detailed information on individual players and products. In particular, we find the Executive Summary very effective and were able to use it very well for our purposes.
We have already recommended the report to some of our partners and are already looking forward to the 2019 edition."
Mathew Farag
Chief Operating Officer
Cyclopharm Limited
The Crescent Kingsgrove, NSW, Australia
"Thanks for the great report you supplied us. When we first went searching for information on Nuclear Medicine we found it very difficult to locate real data. The MEDraysintell report gives us actual data clearly collected by people who understand the industry and not just by a call centre. It was very discretely organised to allow us to search based on product or company. An all-round great report."
Dr. Andreas Eckert
Chief Executive Officer
Eckert & Ziegler AG
Berlin, Germany
"I have another target we are looking at, XYZ. Would you be able to compile me a similar dossier as for ABC? The one of yesterday was really excellent.”
Client-specific intelligence
Dr. Edgard Löffler
Chief Executive Officer
Eckert & Ziegler BEBIG
Belgium, Germany
"Paul-Emmanuel wrote a full world market review for one of the market we were interested in. When it was done and I showed it to some industry insiders, they were very impressed by the level and excellence of the information.”
Client-specific intelligence
Banu Evliyazade
Business Development Director
Eczacıbaşı-Monrol
Istanbul, Turkey
"We believe that the MEDraysintell report is the only one that reflects the Nuclear Medicine Industry’s dynamics in a more comprehensive way. We highly recommend this report to others.”
James Cook
Chief Executive Officer
Evergreen Theragnostics, Inc.
Jersey City, NJ, USA
"There are a lot of companies that advertise market reports, but it is rare to find one with real expertise in Nuclear Medicine. The MEDraysintell report really stands alone in both its comprehensive global look at the industry and the depth and understanding it applies. It has been valuable for both for scanning early investigational products, and in providing thoughtful analysis on industry growth trends. It is also our go to resource for new team members just getting into the industry to get a thorough understanding of the landscape.”
Erik Strömqvist
General Manager, Cyclotrons & TRACERcenter,
Uno Zetterberg
Global Sales Director
GE Healthcare
Uppsala, Sweden
"For the first time we have access to a third party report addressing our specific market. This becomes an additional input to our internal market analysis which will eventually help shaping our road map and strategy. The Cyclotrons report presents quite detailed data both in terms of equipment types as well as relevant regional dynamics and data. We are happy to recommend this report to anyone acting in the field of medical cyclotrons and it is highly likely we will purchase future reports from MEDraysintell.”
Pierre Mottet
CEO
IBA
Louvain-la-Neuve, Belgium
"During his years at IBA, Paul-Emmanuel was very helpful in bringing detailed analysis on markets and competitors. In addition he developed a process to help us better structure our strategic intelligence system. I was impressed by the quality of information he provided, so well reported, concisely and clearly.”
Client-specific intelligence
James F. Clouser
Past-President
IBA
California, USA
"As the former President of a Belgian-based, high technology company who was hired to integrate and develop a strategic plan for a company that had made 9 acquisitions over an 18 month period, I found Paul-Emmanuel a valuable, indispensable member of the senior management team. His thoughtful, high-level insights combined with his technical ability to access hard-to-find data gave the company unique insights into a winning direction for the company. I can give no higher compliment than to say that if I were to either manage or be a member of a board of directors of a company in Europe again, Paul-Emmanuel would be on the short list of people I would contact immediately to help me.”
Client-specific intelligence
"Paul-Emmanuel always made very sharp and detailed analyses on companies. His financial reports have been truly instrumental in helping better understand the businesses we were looking at.”
Client-specific intelligence
Erik Flatmark
Division Director, Radiopharmacy Division
IFE -Institute for Energy Technology
Kjeller, Norway
"The reports we have bought from MEDraysintell have definitely met our expectations. Compared to similar reports from other vendors, the ones from MEDraysintell are clearly prepared by experts in the field, with hands-on knowledge and updated data of the full value chain. For a small CDMO like ours, the reports have been vital for us in finalizing our strategy work last year.”
Ira N. Goldman
Director, Strategic Product Supply
and Government Relations
Lantheus Medical Imaging
N. Billerica, MA, USA
"There are a variety of reports that purport to review the nuclear medicine market. However, the MEDraysintell nuclear medicine report is by far the single most comprehensive report with a worldwide view of the current and near-term projected market situation. It contains detailed information regarding radioisotopes and radiopharmaceuticals, past, present and future, both for diagnostic and therapeutic uses. In the months since we purchased the report, I have reached for it almost every day in response to requests for information. It has truly become my “bible” for information on medical radioisotopes and radiopharmaceuticals. I highly recommend this report.”
Marco G. Renoldi
Chief Operating Officer
Nordic Nanovector ASA
Oslo, Norway
"In the pharmaceutical and biotech industries we are used to consult market reports that are focused on a specific disease, and assess multiple technologies and products/projects only within that space. The MEDraysintell nuclear medicine report, on the other side, is focused on a specific technology and covers its multiple applications – whether diagnostic or therapeutic - across all indications/diseases. This is a diverse and healthy perspective, as Nuclear Medicine is a somewhat special discipline that deserves its own space. I found the MEDraysintell report very thorough, actually the most thorough review of competitive projects in this field. The report helped us clarify specific features of competitive projects and will be a useful companion as we refine our development and commercialization strategies moving forward. It provides great value for money and I would recommend it to other colleagues who operate in this field."
Piet Louw
Executive Manager
NTP Radioisotopes SOC Ltd.
Pretoria, South Africa
"The reports on ‘Opportunities in Brachytherapy, Edition 2014’ and ‘Opportunities in Nuclear Medicine, Edition 2014 and Update’ were very useful to assist NTP in gaining a better understanding of the markets and products of interest as they covered the subject matter in great depth and breadth. Importantly, the reports have helped NTP to make various business and marketing decisions and to gain a deeper insight into the subject matter and industry role players. The graphical presentations of facts and figures are excellent and useful, especially for the purposes of presenting strategic information within the company at executive level. The layout of the reports as well as the way they are indexed makes for easy access to data of interest and the reports have become widely consulted within our organization, testimony to their usefulness. NTP recommends the products that it has thus far acquired from MEDraysintell and looks forward to an ongoing relationship with them."
Paul De Keyser
Business Development Advisor
SCK•CEN
Mol, Belgium
"The MEDraysintell report on Nuclear Medicine is unique, especially the level of detail on aspects such as medical applications, production and pricing, as well as issues and trends which exceeded my expectations. Despite the respectable volume of this report (nearly 1000 pages!) it is very easy to look up specific items…and I keep on using it as a reference, as there's such a wealth of information! The report adds value to our own activity as I need to have up-to-date market data in order to make sound recommendations regarding some of our center's strategic directions. The report was instrumental in reaching that goal. I strongly recommend this report to others.”
Jan Timmer
Head of Marketing-Particle Therapy
Varian Medical Systems, Inc.
Palo Alto, CA, USA
With his Proton Therapy report Paul-Emmanuel has given the industry eyes and ears. When these data were not available in the past, people were more or less making up their own numbers. The report is a must-read for market participants and investors, and I am looking forward to an annual update."
Geert Bosmans, PhD
Project Director
ZONPTC Zuid-Oost Nederland Protonen Therapie Centrum
Maastricht, The Netherland
“The Proton Therapy reports is an exhaustive compilation of information about the proton therapy market. We purchased the report from 2012 as well as the 2015 Edition, with a lot of new insights and future outlook. The report reflects an independent view on this, rather new, market. It helped us in finalizing our business plan by supporting our hypotheses with data. Some information is already available on the internet, but this report saves you a lot of time and will certainly be an added value. I would recommend to buy this report for people entering the world of proton therapy.”